Abbott has received marketing authorisation from the European Commission for once-daily dosing of Kaletra (lopinavir/ritonavir) tablet, the company’s lead HIV protease inhibitor (PI), in adult patients new to
Antisense Pharma (Antisense) has received orphan drug designation from both the European Medicines Agency (EMEA) and the FDA for its investigational drug, trabedersen, in the treatment of pancreatic
Schering-Plough has revealed final results of a Saphris long-term schizophrenia relapse prevention clinical study. In the double-blind phase of the study, time to relapse or impending relapse, the
Aastrom Biosciences has reported revenues of $69,000 consisting of product sales for the fourth quarter ended June 30,2009, a decrease when compared to $149,000 for the fourth quarter
Inspire Pharmaceuticals has committed to increasing production of AzaSite in response to the manufacturing supply shortage of erythromycin ophthalmic ointment (0.5%). The FDA has placed erythromycin ophthalmic ointment
Digestive Care (DCI) has received a complete response letter from the FDA and has moved closer to obtaining approval of its New Drug Application (NDA) for Pancrecarb (pancrelipase).
Mpex Pharmaceuticals (Mpex) has reported positive top line results from a phase 2b clinical trial with Aeroquin, a new aerosol formulation of levofloxacin delivered by an optimised Investigational
Tobira Therapeutics (Tobira) has reported pharmacokinetic data and results from a double-blind, placebo-controlled, multiple-dose randomised study of TBR-652 in sixty healthy volunteers. TBR-652, a CCR5 antagonist under investigation
Schering-Plough has reported long-term data with vicriviroc, its investigational CCR5 receptor antagonist, from an ongoing, open-label extension of the phase II VICTOR-E1 study in treatment-experienced HIV-infected patients. The
Protalix Biotherapeutics (Protalix) has completed its pivotal phase III trial for prGCD, the company’s proprietary plant-cell expressed recombinant form of glucocerebrosidase (GCD) for the treatment of Gaucher disease.
Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.